Lipigon Pharmaceuticals Ab Stock Earnings Per Share
| LPGO Stock | SEK 0.17 0.01 5.56% |
Lipigon Pharmaceuticals AB fundamentals help investors to digest information that contributes to Lipigon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Lipigon Stock. The fundamental analysis module provides a way to measure Lipigon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lipigon Pharmaceuticals stock.
Lipigon |
Lipigon Pharmaceuticals AB Company Earnings Per Share Analysis
Lipigon Pharmaceuticals' Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current Lipigon Pharmaceuticals Earnings Per Share | (4.65) X |
Most of Lipigon Pharmaceuticals' fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Lipigon Pharmaceuticals AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
According to the company disclosure, Lipigon Pharmaceuticals AB has an Earnings Per Share of -4.652 times. This is 155.58% lower than that of the Healthcare sector and 2.88% lower than that of the Biotechnology industry. The earnings per share for all Sweden stocks is notably higher than that of the company.
Lipigon Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Lipigon Pharmaceuticals' direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Lipigon Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Lipigon Pharmaceuticals by comparing valuation metrics of similar companies.Lipigon Pharmaceuticals is currently under evaluation in earnings per share category among its peers.
Lipigon Fundamentals
| Return On Equity | -1.7 | |||
| Return On Asset | -0.94 | |||
| Operating Margin | (338.33) % | |||
| Current Valuation | 5.58 M | |||
| Shares Outstanding | 20.24 M | |||
| Shares Owned By Insiders | 38.47 % | |||
| Shares Owned By Institutions | 12.51 % | |||
| Price To Book | 1.62 X | |||
| Price To Sales | 147.83 X | |||
| Revenue | 3.18 M | |||
| Gross Profit | (36.04 M) | |||
| EBITDA | (41.09 M) | |||
| Net Income | (41.11 M) | |||
| Cash And Equivalents | 58.95 M | |||
| Cash Per Share | 6.06 X | |||
| Current Ratio | 23.62 X | |||
| Book Value Per Share | 0.65 X | |||
| Cash Flow From Operations | (35.3 M) | |||
| Earnings Per Share | (4.65) X | |||
| Target Price | 5.4 | |||
| Market Capitalization | 25.81 M | |||
| Total Asset | 29.43 M | |||
| Z Score | -3.3 | |||
| Net Asset | 29.43 M |
About Lipigon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lipigon Pharmaceuticals AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lipigon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lipigon Pharmaceuticals AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Lipigon Stock Analysis
When running Lipigon Pharmaceuticals' price analysis, check to measure Lipigon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipigon Pharmaceuticals is operating at the current time. Most of Lipigon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lipigon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipigon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lipigon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.